← Leaderboards
Katherine Nelson Weilbaecher
Washington University
$8,913,824
Attributed
$12,365,161
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,365,161 · 8
By mechanism
R01$9,382,552 · 4
P01$2,312,066 · 2
K08$340,249 · 1
R56$330,294 · 1
Top collaborators
- Gregory M Lanza10 shared
- Dipanjan Pan5 shared
- Christopher A Maher1 shared
Most similar at Washington University
Same institution · by research overlap
- Lee Ratner$26,026,037
- William A Frazier$7,571,651
- Thomas G. Diacovo$10,076,014
- Christine T Pham$10,070,288
- Dipanjan Pan$1,633,276
Others in their field
Top investigators on “Osteoclasts”
- Brendan Hl Lee · Baylor College Of Medicine$18,789,257
- Steven L Teitelbaum · Washington University$16,498,459
- Mone Zaidi · Icahn School Of Medicine At Mount Sinai$16,089,949
- Karl Leonard Insogna · Yale University$15,344,415
- Yi-Ping Li · Tulane University Of Louisiana$14,733,549
- Yongwon Choi · University Of Pennsylvania$14,421,139
Research focus
OsteoclastsTumorBoneCellsMalignant NeoplasmsTumor GrowthBone NeoplasmsTumor ProgressionChemotherapyNeoplastic CellMetastatic Neoplasm To The BoneNeoplasm MetastasisMediatingOsteolysisDependenceIn VivoMalignant Breast NeoplasmBone LossPathway InteractionsBreastAffectOsteolyticIn VitroPlay
Grant awards (33)
Mechanism of acid signaling in bone organ metastases on tumor and myeloid cell evolution towards immune suppression and tumor progression$645,323
R01 · FY2025 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$610,502
R01 · FY2022 · CA
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2021 · CA
Project 2: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment during tumor growth and progression in ATL$362,735
P01 · FY2021 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2020 · CA
Project 2: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment during tumor growth and progression in ATL$376,735
P01 · FY2020 · CA · contact PI
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$604,272
R01 · FY2019 · CA
OVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPY$622,961
R01 · FY2018 · CA
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$315,567
P01 · FY2018 · CA · contact PI
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$18,280
P01 · FY2018 · CA · contact PI
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$314,365
P01 · FY2017 · CA · contact PI
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$313,489
P01 · FY2016 · CA · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$482,398
R01 · FY2015 · CA
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$312,014
P01 · FY2015 · CA · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$469,056
R01 · FY2014 · CA
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$349,620
R01 · FY2014 · CA · contact PI
Project 3: Effect of HTLV-1 Viral Oncogenes on the Bone Microenvironment in ATL$298,881
P01 · FY2014 · CA · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$455,665
R01 · FY2013 · CA
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$338,806
R01 · FY2013 · CA · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$485,959
R01 · FY2012 · CA
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$360,433
R01 · FY2012 · CA · contact PI
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERY$487,193
R01 · FY2011 · CA
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$360,433
R01 · FY2011 · CA · contact PI
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$165,148
R01 · FY2010 · CA · contact PI
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASIS$330,294
R56 · FY2009 · CA · contact PI
Role of Beta 3 Integrin in Skeletal Metastasis$322,785
R01 · FY2007 · CA · contact PI
Role of Beta 3 Integrin in Skeletal Metastasis$354,801
R01 · FY2006 · CA · contact PI
Role of Beta 3 Integrin in Skeletal Metastasis$340,425
R01 · FY2005 · CA
Role of Beta 3 Integrin in Skeletal Metastasis$340,425
R01 · FY2004 · CA
Role of Beta 3 Integrin in Skeletal Metastasis$340,425
R01 · FY2003 · CA
MICROPHTHALMIA IN OSTEOCLAST DEVELOPMENT$121,311
K08 · FY2002 · AG
MICROPHTHALMIA IN OSTEOCLAST DEVELOPMENT$117,569
K08 · FY2001 · AG
MICROPHTHALMIA IN OSTEOCLAST DEVELOPMENT$101,369
K08 · FY2000 · AG